カテゴリ： GlobalData, アメリカ, 企業調査

Cellular Biomedicine Group Inc (CBMG)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Cellular Biomedicine Group Inc (CBMG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8264
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：58
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Cellular Biomedicine Group Inc (CBMG) is a clinical stage biopharmaceutical firm that develops biomedicine, immunotherapy products for cancer and stem cell therapies to address patient specific medical conditions. The firm’s products comprise clinical treatment protocols for the treatment of knee osteoarthritis, cancer, asthma and chronic obstructive pulmonary diseases. It offers treatment protocol services such as orthopaedic diseases including osteoarthritis and tissue damage; and other indications. CBMG utilizes proprietary cell based technologies to produce raw material, manufacture cells, and conduct cell banking and distribution. The firm has operations in Hong Kong, China and the US. CBMG is headquartered in Cupertino, California, the US.

Cellular Biomedicine Group Inc (CBMG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cellular Biomedicine Group Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Cellular Biomedicine Acquires Rights to CD40LGVAX Vaccine 13
Cellular Biomedicine Acquires CAR-T Immuno-Oncology Technology and Clinical Data from PLA General Hospital 15
Cellular Biomedicine to Acquire Chimeric Antigen Receptor from PersonGen Biomedicine 16
Venture Financing 17
Cellular Biomedicine Raises US$7 Million In Venture Financing 17
Private Equity 18
Sailing Capital Overseas Invests USD30.6 Million in Cellular Biomedicine 18
Partnerships 19
Cellular Biomedicine Enters Into Licensing Agreement With Hsu-Wei Fang For ProCellar 19
Cellular Biomedicine Forms Joint Venture with Thermo Fisher Scientific 20
Cellular Biomedicine Enters Co-Development Agreement with GE Healthcare Life Sciences China 21
Merger 22
EastBridge Investment Group And Cellular Biomedicine Group Complete Merger 22
Licensing Agreements 23
Cellular Biomedicine Enters into Licensing Agreement with National Cancer Institute 23
Novartis Enters into Licensing Agreement with Cellular Biomedicine 24
Cellular Biomedicine Enters into Option Agreement with Augusta University 26
NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 27
Equity Offering 28
Cellular Biomedicine Plans to Raise up to USD25.5 Million in Public Offering of Shares 28
Cellular Biomedicine Raises USD14 Million in Private Placement of Shares 29
Cellular Biomedicine to Raise Funds through Public Offering of Shares 30
Cellular Biomedicine to Raise Up to USD50 Million in Issue of Shares 31
Cellular Biomedicine Raises USD19.6 Million in Private Placement of Shares 32
Acquisition 33
Wuhan Dangdai Science & Technology Acquires 19.4% Stake in Cellular Biomedicine for USD43.13 Million 33
Cellular Biomedicine Group Inc – Key Competitors 34
Cellular Biomedicine Group Inc – Key Employees 35
Cellular Biomedicine Group Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 37
Recent Developments 38
Strategy And Business Planning 38
Jun 22, 2018: Cellular Biomedicine Group Announces Grand Opening of Global Research and Development Center in Gaithersburg, Maryland 38
Nov 07, 2017: Cellular Biomedicine Group Opens its New Shanghai GMP Facility and Joint Laboratory 39
Sep 22, 2017: Cellular Biomedicine Group Plans Grand Opening of its New Shanghai Facility 40
Mar 30, 2017: Cellular Biomedicine Group Announces Completion of Wuxi GMP Facility Expansion 41
Jan 03, 2017: Expansion of Cell Production to Produce CAR-T Therapies 42
Financial Announcements 43
Aug 08, 2018: Cellular Biomedicine Group announce second quarter and first half 2018 financial results and business highlights 43
May 08, 2018: Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress 44
Mar 06, 2018: Cellular Biomedicine Group Reports Full Year 2017 Financial Results 45
Nov 09, 2017: Cellular Biomedicine Group Reports Third Quarter Financial Results and Recent Operational Highlights 47
Aug 08, 2017: Cellular Biomedicine Group Reports Second Quarter and First Half 2017 Financial Results and Business Highlights 49
May 08, 2017: Cellular Biomedicine Group Reports First Quarter 2017 Financial Results and Provides Business Highlights 50
Mar 13, 2017: Cellular Biomedicine Group Reports Full-Year 2016 Financial Results and Recent Operational Progress 51
Corporate Communications 53
Jun 20, 2017: Cellular Biomedicine Group Appoints Michael A. Caligiuri, MD as Chair of External Advisory Board 53
Product News 54
05/19/2017: Cellular Biomedicine Group Announces Publication Titled “Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody” in Conjunction with 2017 ASCO Annual Meeting 54
Clinical Trials 55
Jan 09, 2017: Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in China 55
Other Significant Developments 56
Apr 30, 2018: Cellular Biomedicine Group Announces Results of 2018 Annual Meeting of Stockholders 56
Jan 18, 2018: CBMG Accelerates Cell Therapy Manufacturing with GE Healthcare’s New Start-to-Finish Solution 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cellular Biomedicine Group Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cellular Biomedicine Group Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cellular Biomedicine Acquires Rights to CD40LGVAX Vaccine 13
Cellular Biomedicine Acquires CAR-T Immuno-Oncology Technology and Clinical Data from PLA General Hospital 15
Cellular Biomedicine to Acquire Chimeric Antigen Receptor from PersonGen Biomedicine 16
Cellular Biomedicine Raises US$7 Million In Venture Financing 17
Sailing Capital Overseas Invests USD30.6 Million in Cellular Biomedicine 18
Cellular Biomedicine Enters Into Licensing Agreement With Hsu-Wei Fang For ProCellar 19
Cellular Biomedicine Forms Joint Venture with Thermo Fisher Scientific 20
Cellular Biomedicine Enters Co-Development Agreement with GE Healthcare Life Sciences China 21
EastBridge Investment Group And Cellular Biomedicine Group Complete Merger 22
Cellular Biomedicine Enters into Licensing Agreement with National Cancer Institute 23
Novartis Enters into Licensing Agreement with Cellular Biomedicine 24
Cellular Biomedicine Enters into Option Agreement with Augusta University 26
NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 27
Cellular Biomedicine Plans to Raise up to USD25.5 Million in Public Offering of Shares 28
Cellular Biomedicine Raises USD14 Million in Private Placement of Shares 29
Cellular Biomedicine to Raise Funds through Public Offering of Shares 30
Cellular Biomedicine to Raise Up to USD50 Million in Issue of Shares 31
Cellular Biomedicine Raises USD19.6 Million in Private Placement of Shares 32
Wuhan Dangdai Science & Technology Acquires 19.4% Stake in Cellular Biomedicine for USD43.13 Million 33
Cellular Biomedicine Group Inc, Key Competitors 34
Cellular Biomedicine Group Inc, Key Employees 35
Cellular Biomedicine Group Inc, Other Locations 36
Cellular Biomedicine Group Inc, Subsidiaries 36
Cellular Biomedicine Group Inc, Joint Venture 37

List of Figures
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cellular Biomedicine Group Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Cellular Biomedicine Group Inc (CBMG)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • HSBC Trinkaus & Burkhardt AG (TUB)：企業の財務・戦略的SWOT分析
    HSBC Trinkaus & Burkhardt AG (TUB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • MicroPort Scientific Corp (853)：企業の財務・戦略的SWOT分析
    Summary MicroPort Scientific Corp (MicroPort) operates as a medical device company that develops, manufactures and markets cardiovascular treatment devices. The company provides products such as cardiovascular devices, orthopedic devices, endovascular devices, electronic laparoscope devices, neurova …
  • COWI AS：企業の戦略的SWOT分析
    COWI AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Bausch & Lomb Inc：企業の戦略的SWOT分析
    Bausch & Lomb Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Walchandnagar Industries Ltd：企業の戦略・SWOT・財務情報
    Walchandnagar Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Walchandnagar Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Total SA (FP)-エネルギー分野：企業M&A・提携分析
    Summary Total S.A. (Total) is an integrated global oil and gas company that produces, refines and markets oil, and also manufactures petrochemicals. It carries out drilling, oil and gas production, processing, transportation, refining and petrochemical production, storage and distribution of petrole …
  • Fusion Telecommunications International, Inc.：企業のM&A・事業提携・投資動向
    Fusion Telecommunications International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fusion Telecommunications International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, …
  • BiondVax Pharmaceuticals Ltd (BVXV)：企業の財務・戦略的SWOT分析
    Summary BiondVax Pharmaceuticals Ltd (BiondVax Pharmaceuticals) is a biopharmaceutical company that develops universal flu vaccine. The company provides lead product M-001 is a synthetic peptide-based protein that offers protection against human influenza virus strains including seasonal influenza s …
  • Vexim SA – Product Pipeline Analysis, 2018 Uate
    Summary Vexim SA (Vexim), a subsidiary of Stryker Corp, is a healthcare product manufacturer that provides solutions for patients suffering from vertebral compression fractures. The company provides solutions such as controlled anatomical restoration and advanced vertebroplasty therapy. Its controll …
  • Generex Biotechnology Corp (GNBT)：医療機器：M&Aディール及び事業提携情報
    Summary Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company’s proprietary liquid formulatio …
  • MEDITE Cancer Diagnostics Inc (MDIT)：企業の財務・戦略的SWOT分析
    MEDITE Cancer Diagnostics Inc (MDIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Agilent Technologies Inc (A)：企業の財務・戦略的SWOT分析
    Agilent Technologies Inc (A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Arafura Resources Ltd：企業の戦略・SWOT・財務情報
    Arafura Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Arafura Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • GrowMax Resources Corp (BOE)：企業の財務・戦略的SWOT分析
    Summary GrowMax Resources Corp (GrowMax), formerly Americas Petrogas Inc is an oil and gas company that offers exploration and development of conventional and unconventional oil and gas properties in Argentina. The company explores and develops phosphate and potassium-rich brine resources in northwe …
  • Zain Group：企業の戦略・SWOT・財務分析
    Zain Group - Strategy, SWOT and Corporate Finance Report Summary Zain Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Gulf Oil Limited Partnership：企業の戦略・SWOT・財務情報
    Gulf Oil Limited Partnership - Strategy, SWOT and Corporate Finance Report Summary Gulf Oil Limited Partnership - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Abzena Plc (ABZA)-製薬・医療分野：企業M&A・提携分析
    Summary Abzena Plc (Abzena), formerly Polytherics Group Ltd is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company's technologies include a …
  • Qantas Airways Ltd (QAN)：企業の財務・戦略的SWOT分析
    Qantas Airways Ltd (QAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • G1 Therapeutics Inc (GTHX)-製薬・医療分野：企業M&A・提携分析
    Summary G1 Therapeutics Inc (G1 Therapeutics), formerly G Zero Therapeutics Inc is a healthcare company that develops novel, and small molecule therapies. The company pipeline products include CDK4/6, trilaciclib G1T28 a drug candidate; G1T38 a potential best compound, and G1T48. It undertakes disco …
  • Accu-Break Pharmaceuticals Inc-製薬・医療分野：企業M&A・提携分析
    Summary Accu-Break Pharmaceuticals Inc (Accu-Break) is a developer and provider of pharmaceutical tablet technologies for accurate and customized dosing. The company provides services such as patented technologies, product differentiation, life cycle management, APIs solutions, product enhancement, …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆